A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 4, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE)

Intervention/treatment:
LEBRIKIZUMAB (LY3650150)
Medical condition:
ATOPIC DERMATITIS
Protocol code:
J2T-MC-KGCE
Control number:
298473
Status:
Active, not recruiting
Approved:
June 26, 2025
Trial phase:
Phase 4
For more information:
ClinicalTrials.gov - NCT07006792
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
12 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Role
CONTACT
Phone:
1-317-615-4559
Name
Physicians interested in becoming principal investigators please contact
Role
CONTACT
Sponsor
ELI LILLY CANADA INC

Locations

Brunswick Dermatology Center
Fredericton, E3B 1G9
ACTIVE_NOT_RECRUITING
Name
Irina Turchin
Role
PRINCIPAL_INVESTIGATOR
Phone:
4032633376
Centre de Recherche Saint-Louis
Sherbrooke, J1G 1X9
ACTIVE_NOT_RECRUITING
Role
CONTACT
Phone:
905-773-1599
Name
Michael Corbo
Role
PRINCIPAL_INVESTIGATOR
Eternal Springtime Dermatology
Thunder Bay, P7C 4Y7
ACTIVE_NOT_RECRUITING
Name
Melinda Gooderham
Role
CONTACT
Phone:
888-728-9142
Name
Evelyn Alarcon Chinchilla
Role
PRINCIPAL_INVESTIGATOR
Kanata Allergy Clinic
Ottawa, K2T 0N7
ACTIVE_NOT_RECRUITING
Name
Fiona Lovegrove
Role
CONTACT
Phone:
613-212-7165
Name
Ahmed Ahmed
Role
PRINCIPAL_INVESTIGATOR
Lovegrove Dermatology
London, N6A 5R9
ACTIVE_NOT_RECRUITING
Name
Fiona Lovegrove
Role
PRINCIPAL_INVESTIGATOR
Maritime Dermatology
Halifax, B3K 5R3
COMPLETED
Name
Natalie Cunningham
Role
PRINCIPAL_INVESTIGATOR
North York Research Inc
Toronto, M2N 3A6
ACTIVE_NOT_RECRUITING
Name
Anastasia Shamsuyarova
Role
PRINCIPAL_INVESTIGATOR
Phone:
905-773-1599
Skin Care West
Nanaimo, V9V 1A3
ACTIVE_NOT_RECRUITING
Name
Gabriele Weichert
Role
PRINCIPAL_INVESTIGATOR
SKiN Centre for Dermatology
Peterborough, K9J 5K2
COMPLETED
Name
Melinda Gooderham
Role
PRINCIPAL_INVESTIGATOR
Did you find what you were looking for?

Contacts and resources